SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13969)1/30/1998 3:42:00 PM
From: rocket  Respond to of 32384
 
Henry--its been a while since i've posted here but i just wanted to say i'm more hopeful that the whole biotech sector may benefit from the FDA's approval of products from ATIS and ORG. Seems to me that alot of the tier 2 and 3 biotech firms rise and fall with what the whole sector is doing. The biotech sector has been in a swoon for nigh 2 years now, partly because of so many rejections by the FDA. Maybe now more institutional money will start flowing into the sector as many firms are into phase iii trials and FDA approval is (hopefully) close behind. LGND's pipeline is certainly full and sooner or later investior will recognize this. Best wishes. karl



To: Henry Niman who wrote (13969)1/30/1998 4:12:00 PM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
Let's take the opposite side of the coin. If one can manipulate a dormant gene to produce hair, isn't it possible to manipulate the same gene, if it is just one gene, to get rid of hair. What I'm getting at is that there is also a big business in trying to get rid of unwanted hair. Could Lgnd theoretically become a player in this aspect?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News